CRL - Charles River Laboratories International, Inc.
133.69 +0.06 (0.04%)
After hours: 4:14PM EST
| Previous Close | 136.45 |
| Open | 136.32 |
| Bid | 116.51 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 133.15 - 136.92 |
| 52 Week Range | 96.70 - 138.89 |
| Volume | 519,332 |
| Avg. Volume | 396,335 |
| Market Cap | 6.43B |
| Beta (3Y Monthly) | 0.66 |
| PE Ratio (TTM) | 48.12 |
| EPS (TTM) | 2.78 |
| Earnings Date | Feb 11, 2019 - Feb 15, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 140.67 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of CRL earnings conference call or presentation 7-Nov-18 1:30pm GMT
Q3 2018 Charles River Laboratories International Inc Earnings Call
Markit•2 days agoSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
Motley Fool•5 days agoCharles River Laboratories International Inc (CRL) Q3 2018 Earnings Conference Call Transcript
CRL earnings call for the period ending September 29, 2018.
- Simply Wall St.•5 days ago
Charles River Laboratories International Inc (NYSE:CRL): Will The Growth Last?
Looking at Charles River Laboratories International Inc’s (NYSE:CRL) earnings update in June 2018, it seems that analyst forecasts are substantially optimistic, with profits predicted to ramp up by an impressive Read More...
- Zacks•5 days ago
Charles River Laboratories (CRL) Q3 Earnings and Revenues Top Estimates
Charles River (CRL) delivered earnings and revenue surprises of 10.87% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 days ago
Charles River: 3Q Earnings Snapshot
The Wilmington, Massachusetts-based company said it had net income of $1.22 per share. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results surpassed Wall Street expectations. ...
- Business Wire•5 days ago
Charles River Laboratories Announces Third-Quarter 2018 Results
– Third-Quarter Revenue of $585.3 Million –
Markit•10 days agoSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
- Business Wire•13 days ago
Charles River to Present Collaborative Methods at Neuroscience 2018
Charles River Laboratories International, Inc. (CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). Throughout the conference, Charles River experts will be presenting posters and hosting discussions on the latest innovations in neuroscience research, including innovative tools and applications for research on drugs targeting Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis, and other neurological disorders.
- GlobeNewswire•14 days ago
Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•18 days ago
Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform
New partnership allows Charles River’s clients access to Distributed Bio’s antibody discovery platforms
- Business Wire•27 days ago
Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases
Charles River Laboratories International, Inc. (CRL) today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the National Institutes of Health (NIH). Under NIAID’s Division of Intramural Research animal care program, Charles River will manage and provide staffing for NIAID’s on-site vivarium and related research model operations. The program is required to ensure the humane care and use of research models, and the efficient management of NIAID’s research model operations.
Markit•last monthSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
- Business Wire•last month
Charles River Laboratories Schedules Third-Quarter 2018 Earnings Release and Conference Call
Charles River Laboratories International, Inc. will release third-quarter 2018 financial results on Wednesday, November 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 7th, at 8:30 a.m.
- Reuters•last month
Cancer center CEO leaves Merck board after disclosure scandal
The New York Times previously reported Thompson's resignation from Merck and from lab services company Charles River Laboratories International Inc. The move follows the resignation of Sloan Kettering's chief medical officer, Jose Baselga, in September, after a New York Times and Pro Publica investigation revealed that he had not disclosed millions of dollars in payments from health-care companies in many of his research articles.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CRL earnings conference call or presentation 8-Aug-18 12:30pm GMT
Q2 2018 Charles River Laboratories International Inc Earnings Call
- Simply Wall St.•2 months ago
Why Charles River Laboratories International Inc’s (NYSE:CRL) ROE Of 10.8% Does Not Tell The Whole Story
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. CharlesRead More...
- Business Wire•2 months ago
Charles River Laboratories to Present at September Investor Conferences
Charles River Laboratories International, Inc. announced today that it will present at three upcoming investor conferences, including:
Markit•3 months agoSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
- ACCESSWIRE•3 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Charles River Laboratories International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- Zacks•3 months ago
Charles River Laboratories (CRL) Beats Q2 Earnings and Revenue Estimates
Charles River (CRL) delivered earnings and revenue surprises of 10.96% and 2.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Charles River: 2Q Earnings Snapshot
On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.10. Earnings, adjusted for one-time gains and costs, came to $1.62 per share. The results beat Wall Street expectations. ...
- Business Wire•3 months ago
Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations
– Second-Quarter Revenue of $585.3 Million –
- Zacks•3 months ago
Can Tenet Healthcare (THC) Keep Earnings Beat Alive in Q2?
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.
Markit•3 months agoSee what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Charles River Laboratories International Inc NYSE:CRL
